Work

Supplementary Figure S4 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Year: 2023

Type: supplementary-materials

Abstract: Tarloxotinib (prodrug) is less effective against WT and mutant forms of EGFR and HER2.

DOI: 10.1158/1078-0432.22478573.v1

Authors: Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361938378

Cites:

Cited by:

Related to: 10